Spero Therapeutics Inc., of Cambridge, Mass., has set terms for its IPO and will sell 5 million shares of common stock priced between $14 and $16 per share. Its lead candidate SPR-994 is an oral formulation of tebipenem pivoxil designed as the first broad-spectrum oral carbapenem-class antibiotic to treat adults with multidrug-resistant (MDR) gram-negative infections, with the goal of preventing hospitalizations for serious infections and enabling earlier treatment of patients following hospitalization. The initial target is complicated urinary tract infections. The company has applied to list its common stock on the Nasdaq Global Market under the symbol SPRO. (See BioWorld, Oct.10, 2017.)